BAL PHARMA LTD. - 524824 - Corporate Action-Board to consider Dividend
Please refer to our intimation regarding Board Meeting dated 30.04.2024.03-05-2024
03-05-2024
BAL PHARMA LTD. - 524824 - Board Meeting Intimation for Notice For The Board Meeting
BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2024 ,inter alia, to consider and approve 1.Audited Standalone and Consolidated financial results for the quarter and financial year ended 31.03.2024. 2.Audited standalone and consolidated accounts of the Company together with Directors and Auditors reports. 3. Recommendation of Dividend, if any, for the financial year ended 31.03.2024. 4.Appoinment of Internal Auditors, Cost Auditors and Secretarial Auditors for f.y ended 31.03.2024.30-04-2024
BAL PHARMA LTD. - 524824 - Disclosure Of Statement Of Deviation/Veriation
Disclosure of Deviation / variation in utilization of issue proceeds from the objects stated in the explanatory statement to the notice of the general meeting for the quarter ended 31.03.2024 is not applicable for our Company i.e Bal Pharma Limited , as the preferential issue proceeds has been fully utilized.18-04-2024
BAL PHARMA LTD. - 524824 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
We are submitting to the exchange intimation received from our R&T agent i.e Link Intime India Private Ltd, Mumbai regarding loss of share certificate by one of our shareholder.17-04-2024
BAL PHARMA LTD. - 524824 - Compliance With Regulation 40(9) Of SEBI(LODR) Regulations.
Compliance certificate as per Regulation 40(9) of SEBI(LODR) Regulations , for the financial year ended 31.03.2024.15-04-2024
BAL PHARMA LTD. - 524824 - Disclosures As Per Regulation 31(4) Of SEBI(SAST) Regulations.
We are submitting to the exchange disclosures by our promoters as per Regulation 31(4) of SEBI(SAST) Regulations for the financial year ended 31.03.2024.05-04-2024
BAL PHARMA LTD. - 524824 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Confirmation as per Regulation 74(5) of SEBI (DP) Regulations for the quarter ended 31.03.2024.05-04-2024
BAL PHARMA LTD. - 524824 - Regulation 7(3) Certificate For The Financial Year Ended 31.03.2024.
Compliance certificate as per Regulation 7(3) of SEBI(LODR) Regulations,2015.04-04-2024
BAL PHARMA LTD. - 524824 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyBAL PHARMA LTD. 2CIN NO.L85110KA1987PLC008368 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 44.81 4Highest Credit Rating during the previous FY BBB- 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)ACUITE RATINGS & RESEARCH LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Abdul Basith Designation: Company Secretary EmailId: [email protected] Name of the Chief Financial Officer: Bharath Bhushan Designation: CFO EmailId: [email protected] Date: 02/04/2024 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.02-04-2024
BAL PHARMA LTD. - 524824 - Closure of Trading Window
Pursuant to the Code of Conduct of the Company and as per the amended provisions of SEBI(Prohibition of Insider Trading) Regulations,2015, We wish to inform the exchanges that the trading window for dealing with the securities of the Company on the designated persons and their immediate relatives will be closed from 1st April 2024 and up to 48 hours of the declaration of the Audited Financial Results of the Company for the quarter and financial year ended 31.03.2024. The date of the Board meeting for declaration of audited financial results will be intimated to the exchanges in due course.22-03-2024